المؤلفون: Véronique Bédoucha, Norbert Gattermann, Philipp le Coutre, Prashanth Gopalakrishna, Jerald P. Radich, Weiping Deng, Susanne Saussele, Eibhlin Conneally, Nancy Krunic, Giuseppe Saglio, Andrzej Hellmann, Bruno Martino, Francis J. Giles, Valentín García-Gutiérrez, Tamás Masszi, David M. Ross, María Teresa Gómez Casares, Jesper Stentoft, Andreas Hochhaus

المصدر: Journal of Cancer Research and Clinical Oncology
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Ross, D M, Masszi, T, Gómez Casares, M T, Hellmann, A, Stentoft, J, Conneally, E, Garcia-Gutierrez, V, Gattermann, N, le Coutre, P D, Martino, B, Saussele, S, Giles, F J, Radich, J P, Saglio, G, Deng, W, Krunic, N, Bédoucha, V, Gopalakrishna, P & Hochhaus, A 2018, ' Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib : 96-week update of the ENESTfreedom study ', Journal of Cancer Research and Clinical Oncology, vol. 144, no. 5, pp. 945-954 . https://doi.org/10.1007/s00432-018-2604-xTest

مصطلحات موضوعية: Oncology, Male, Cancer Research, Predictors of TFR, Time Factors, Original Article – Clinical Oncology, Kaplan-Meier Estimate, 0302 clinical medicine, Treatment-free remission, hemic and lymphatic diseases, 80 and over, Medicine, Young adult, Chronic, Aged, 80 and over, Hematology, Leukemia, Chronic myeloid leukemia, Remission Induction, Myeloid leukemia, General Medicine, Middle Aged, Protein-Tyrosine Kinases, Clinical trial, Treatment Outcome, 030220 oncology & carcinogenesis, Female, medicine.drug, Adult, medicine.medical_specialty, 03 medical and health sciences, Young Adult, Internal medicine, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Humans, In patient, Frontline, Adverse effect, Aged, business.industry, Nilotinib, Pyrimidines, Major Molecular Response, BCR-ABL Positive, business, 030215 immunology, Myelogenous

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee2d4ac03af448129196634e600efcb4Test
http://europepmc.org/articles/PMC5916993Test

المؤلفون: Arlene Reisman, Bfore Study Investigators, Valentín García-Gutiérrez, Charles Chuah, Carlo Gambacorti-Passerini, Andreas Hochhaus, Michael W. Deininger, Dragana Milojkovic, Rocco J. Crescenzo, Tim H. Brümmendorf, Philipp le Coutre, Carla Mamolo, Jorge E. Cortes, Dong-Wook Kim, Michael J. Mauro

المساهمون: Cortes, J, Gambacorti-Passerini, C, Deininger, M, Mauro, M, Chuah, C, Kim, D, Milojkovic, D, le Coutre, P, Garcia-Gutierrez, V, Crescenzo, R, Mamolo, C, Reisman, A, Hochhaus, A, Brummendorf, T

المصدر: Journal of cancer research and clinical oncology. 145(6)

مصطلحات موضوعية: 0301 basic medicine, Cancer Research, medicine.medical_specialty, Health-related quality of life, Population, Newly diagnosed, Drug Administration Schedule, 03 medical and health sciences, 0302 clinical medicine, Quality of life, hemic and lymphatic diseases, Internal medicine, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Surveys and Questionnaires, Nitriles, Medicine, Humans, Patient Reported Outcome Measures, education, Patient-reported outcome, education.field_of_study, Hematology, Aniline Compounds, business.industry, Chronic myeloid leukemia, Cancer, Imatinib, General Medicine, Chronic phase chronic myeloid leukemia, medicine.disease, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Leukemia, Myeloid, Chronic-Phase, Imatinib Mesylate, Quality of Life, Quinolines, Bosutinib, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e16f05ee7c729b1643915c6e699c795Test
https://pubmed.ncbi.nlm.nih.gov/30989330Test

المؤلفون: Philipp le Coutre, Steven Novick, Michele Baccarani, Francis J. Giles, Helene Santanastasio, Mimi Leung, Andreas Reiter, Hagop M. Kantarjian, Martin C. Müller, Andreas Hochhaus

المصدر: Journal of Cancer Research and Clinical Oncology

مصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Neutrophils, Anemia, Original Article – Clinical Oncology, Tyrosine kinase inhibitor, Neutropenia, Systemic mastocytosis, Gastroenterology, Leukocyte Count, Mastocytosis, Systemic, Internal medicine, medicine, Humans, Adverse effect, Protein Kinase Inhibitors, Indolent systemic mastocytosis, Aggressive systemic mastocytosis, Aged, Retrospective Studies, Myeloproliferative Disorders, business.industry, General Medicine, Middle Aged, Protein-Tyrosine Kinases, Nilotinib, medicine.disease, Discontinuation, Proto-Oncogene Proteins c-kit, Pyrimidines, Treatment Outcome, Oncology, Immunology, Absolute neutrophil count, Female, business, KIT D816V, Progressive disease, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::381606d9fee12d95447c3edf4581b51aTest
https://doi.org/10.1007/s00432-015-1988-0Test

المؤلفون: Tracey McCulloch, Andreas Hochhaus, Philipp le Coutre, Steven Novick, Andreas Reiter, Hagop M. Kantarjian, Francis J. Giles, Michele Baccarani, Philipp Erben, Xiaolin Fan

المصدر: Journal of cancer research and clinical oncology. 139(12)

مصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, medicine.drug_class, Tyrosine-kinase inhibitor, Drug Administration Schedule, Article, Growth factor receptor, Internal medicine, Hypereosinophilic Syndrome, Medicine, Humans, Protein Kinase Inhibitors, Aged, Aged, 80 and over, Chronic eosinophilic leukemia, Hematology, Dose-Response Relationship, Drug, business.industry, Hypereosinophilic syndrome, Organ dysfunction, General Medicine, Middle Aged, medicine.disease, Pyrimidines, Treatment Outcome, Oncology, Nilotinib, Genetic marker, Immunology, Chronic Disease, Female, medicine.symptom, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d87d16b8e1a659015dec7ad1bd52a350Test
https://pubmed.ncbi.nlm.nih.gov/24057647Test

المؤلفون: Philipp le Coutre, Juan Luis Steegmann, Susanne Saussele, Perttu Koskenvesa, Francis J. Giles, Tim H. Brümmendorf, Daniel Coriu, Nicholas C.P. Cross, Jens Haenig, Andreas Hochhaus, Günther Gastl, Gert J. Ossenkoppele, Fausto Castagnetti, Delphine Rea, Gianantonio Rosti, François Xavier Mahon, Ljubomir Petrov, Andrzej Hellmann, Beatrice Vincenzi, Laimonas Griskevicius

المساهمون: CCA - Cancer Treatment and quality of life, Hematology, Department of Medicine, University of Helsinki, Clinicum, Hematologian yksikkö, Department of Oncology, HUS Comprehensive Cancer Center, Giles, Francis J., Rea, Delphine, Rosti, Gianantonio, Cross, Nicholas C. P., Steegmann, Juan Lui, Griskevicius, Laimona, le Coutre, Philipp, Coriu, Daniel, Petrov, Ljubomir, Ossenkoppele, Gert J., Mahon, Francois-Xavier, Saussele, Susanne, Hellmann, Andrzej, Koskenvesa, Perttu, Brã¼mmendorf, Tim H., Gastl, Gunther, Castagnetti, Fausto, Vincenzi, Beatrice, Haenig, Jen, Hochhaus, Andreas

المصدر: Giles, F J, Rea, D, Rosti, G, Cross, N C P, Steegmann, J L, Griskevicius, L, le Coutre, P, Coriu, D, Petrov, L, Ossenkoppele, G J, Mahon, F-X, Saussele, S, Hellmann, A, Koskenvesa, P, Brümmendorf, T H, Gastl, G, Castagnetti, F, Vincenzi, B, Haenig, J & Hochhaus, A 2017, ' Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase : ENEST1st subanalysis ', Journal of Cancer Research and Clinical Oncology, vol. 143, no. 8, pp. 1585-1596 . https://doi.org/10.1007/s00432-017-2402-xTest
Journal of Cancer Research and Clinical Oncology, 143(8), 1585-1596. Springer Verlag
Journal of Cancer Research and Clinical Oncology
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Journal of cancer research and clinical oncology 143(8), 1585-1596 (2017). doi:10.1007/s00432-017-2402-x

مصطلحات موضوعية: Male, Cancer Research, Original Article – Clinical Oncology, Fusion Proteins, bcr-abl, 0302 clinical medicine, hemic and lymphatic diseases, TREATMENT-FREE REMISSION, Prospective cohort study, Aged, 80 and over, Incidence (epidemiology), Chronic myeloid leukemia, CHRONIC MYELOGENOUS LEUKEMIA, General Medicine, Middle Aged, 3. Good health, Clinical trial, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Female, CLINICAL-TRIALS, Human, medicine.drug, Adult, medicine.medical_specialty, 3122 Cancers, IMATINIB MESYLATE, Protein Kinase Inhibitor, CML WORKING PARTY, Molecular response, Disease-Free Survival, 03 medical and health sciences, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Internal medicine, TYROSINE KINASE INHIBITORS, medicine, Humans, Frontline, ddc:610, Adverse effect, Protein Kinase Inhibitors, MOLECULAR RESPONSES, Aged, business.industry, FRONTLINE NILOTINIB, Nilotinib, YOUNGER PATIENTS, medicine.disease, Middle age, Discontinuation, Pyrimidines, Imatinib mesylate, Pyrimidine, Physical therapy, Impact of age, INTERFERON-ALPHA, business, 030215 immunology, Chronic myelogenous leukemia

وصف الملف: application/pdf; text; STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fccc3b0f125ab381bcab5c0041ddaabTest